|
|
Post by tradeup on Nov 20, 2014 18:58:32 GMT
From today's presentation ...
Targeting Late-Stage GA AMD
Primary outcome is anotomical:
- rate of increase of GA of the treated eye compared to fellow eye
Secondary outcomes include:
- OCT
- BCVA
- Low luminance BCVA
- Contrast sensitivity
- Microperimetry
- Reading speed
- VFQ-25
Approx 65 patients
- 3 months of immunosuppression
- 12 months primary endpoint
- option to adjust sample size based on observed outcome variance
|
|
|
|
Post by tradeup on Nov 20, 2014 19:38:50 GMT
Q) Timeline for AMD start?
A) Q1 2015.
Q) How long until commercialization?
A) P2 results by end of 2017.
|
|
|
|
Post by dayanand33 on Nov 26, 2014 20:25:49 GMT
Q) Timeline for AMD start? A) Q1 2015. Q) How long until commercialization? A) P2 results by end of 2017. It means they are spending nearly 3 years in phase 2 amd. Ocata has a shorter duration right? |
|
|
|
Post by dayanand33 on Dec 12, 2014 15:58:45 GMT
From today's presentation ... Targeting Late-Stage GA AMD Primary outcome is anotomical: - rate of increase of GA of the treated eye compared to fellow eye Secondary outcomes include: - OCT - BCVA - Low luminance BCVA - Contrast sensitivity - Microperimetry - Reading speed - VFQ-25 Approx 65 patients - 3 months of immunosuppression - 12 months primary endpoint - option to adjust sample size based on observed outcome variance Tradeup, I have a feeling that Stem is oversold. But to concluding anything, I need to know if there are any near term positive events. As you noted, the AMD P2 results are scheduled in 2017. Do you know of any other trials that could move the needle in the near term? I skimmed through the investor presentation but found it too technical in nature. www.media-server.com/m/p/m8h3mw5w There are about 110 slides but most of them explain the science behind it and talk little about the timelines. |
|
|
|
Post by JHam on Dec 12, 2014 17:20:50 GMT
From today's presentation ... Targeting Late-Stage GA AMD Primary outcome is anotomical: - rate of increase of GA of the treated eye compared to fellow eye Secondary outcomes include: - OCT - BCVA - Low luminance BCVA - Contrast sensitivity - Microperimetry - Reading speed - VFQ-25 Approx 65 patients - 3 months of immunosuppression - 12 months primary endpoint - option to adjust sample size based on observed outcome variance Tradeup, I have a feeling that Stem is oversold. But to concluding anything, I need to know if there are any near term positive events. As you noted, the AMD P2 results are scheduled in 2017. Do you know of any other trials that could move the needle in the near term? I skimmed through the investor presentation but found it too technical in nature. www.media-server.com/m/p/m8h3mw5w There are about 110 slides but most of them explain the science behind it and talk little about the timelines. It is under a dollar now. The biggest near term event I can think of would be a favorable ruling for STEM in their trial vs CUR. |
|
|
|
Post by dayanand33 on Dec 12, 2014 17:52:46 GMT
We should know the outcome of the Stem Vs CUR trial today. It is hard to understand the market as both Stem and Cur are tanking. I thought both would head in opposite direction
|
|
|
|
Post by Jimmywho on Feb 5, 2015 14:41:34 GMT
Safety and Preliminary Efficacy of Human Neural Stem Cells in StemCells, Inc.'s Dry AMD Study to be Presented at Ophthalmology Conference. NEWARK, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine and a principal investigator on StemCells, Inc.'s Phase I/II study in dry age related macular degeneration will be presenting findings on the safety and preliminary efficacy of HuCNS-SC®, human neural stem cells, for dry age related macular degeneration (AMD) at the Angiogenesis, Exudation and Degeneration 2015 symposium. Dr. Leng will present at 12:40 p.m. EST. AMD is the leading cause of blindness in people over the age of 50 and today there are no approved therapies to treat dry AMD. This symposium is hosted by the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. The symposium will be held February 7, 2015 at the Mandarin Oriental Hotel in Miami, Florida. investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=RssLanding&cat=news&id=2013998 |
|
